Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives

Fragment-based drug discovery in recent times has been explored in the design of highly potent therapeutics. In this study, we explored the inhibitory dynamics of Compound 38 (Cpd38), a newly synthesized Bromodomain-containing protein 4 bromodomain 1 (BRD4-BD1) protein inhibitor derived from the syn...

Full description

Saved in:

Bibliographic Details
Published in:	Current pharmaceutical biotechnology Vol. 23; no. 3; p. 444
Main Authors:	Akawa, Oluwole B, Soremekun, Opeyemi S, Olotu, Fisayo A, Solima, Mahmoud E S
Format:	Journal Article
Language:	English
Published:	Netherlands 01-03-2022
Subjects:	Cell Cycle Proteins Drug Discovery Humans Neoplasms Nuclear Proteins Transcription Factors Bromodomain-containing Protein 4 Bromodomain 1 (BRD4-BD1) prostate cancer Fragmentation-based drug discovery bromodomain and extraterminal proteins (BET) chemotherapy molecular dynamics simulation
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Fragment-based drug discovery in recent times has been explored in the design of highly potent therapeutics. In this study, we explored the inhibitory dynamics of Compound 38 (Cpd38), a newly synthesized Bromodomain-containing protein 4 bromodomain 1 (BRD4-BD1) protein inhibitor derived from the synthetic coupling of Fragment 47 (Fgt47) into ABBV-075 scaffold. Using dynamic simulation methods, we unraveled the augmentative effects of chemical fragmentation on improved BRD4- BD1 inhibition. Findings from this study revealed that although Fgt47 exhibited a considerable ΔGbind, its incorporation into the difluoro-phenoxy pyridine scaffold (Cpd38) notably enhanced the binding affinity. Time-based analyses of interaction dynamics further revealed that the bulkiness of Cpd38 favored its interaction at the BRD4-BD1 active site relative to the fragment. Strikingly, compared to Fgt47, Cpd38 demonstrated high mobility, which could have enabled it to bind optimally and complementarily with key residues of the active site such as Ile146, Asn140, Cys136, Tyr98, Leu94, Val87, Phe83, and Trp81. On the contrary, the majority of these interactions were gradually lost in Fgt47, which could further indicate the essence of coupling it with the difluoro-phenoxy pyridine scaffold. Furthermore, Cpd38 had a more altering effect on BRD4-BDI relative to Fgt47, which could also be a result of its higher inhibitory activity. Conclusively, the design of highly potent therapeutics could be facilitated by the incorporation of pharmacologically active small molecule fragments into the scaffold of existing drugs.
ISSN:	1873-4316
DOI:	10.2174/1389201022666210322122056